Key facts
- This page summarizes Mark Eisner's Form 4 filing for FIBROGEN INC (FGEN).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 01 Apr 2022, 19:28.
Mark Eisner - 31 Mar 2022 Form 4 Insider Report for FIBROGEN INC (FGEN)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- FGEN
- Reported as of
- 31 Mar 2022
- Net transaction value
- -$77,433
- SEC form
- 4
- Accepted by SEC
- 01 Apr 2022, 19:28:25 UTC
- Prior SEC filing
- 03 Mar 2022
- Next SEC filing
- 03 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dorothy Pacini, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark Eisner filed Form 4 for FIBROGEN INC (FGEN) on 01 Apr 2022.
Change
- Previous filing in this sequence was filed on 03 Mar 2022.
- Current net transaction value: -$77,433.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FGEN
transaction
Common Stock
Tax liability
- Transaction value
- $77,433
- Shares
- -6,442
- Change %
- -4.1%
- Price
- $12.02*
- Shares after
- 150,941
- Date
- 31 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.